Aggrastat

(Tirofiban Hydrochloride)

Phase 3Small molecule

MMedicure

Aggrastat is one of 68 small molecule programs targeting Prevention. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PreventionUnknown status

Ischemic StrokeNot yet recruiting

PreventionPreclinical

Unknown status

Ischemic StrokePhase 3

Not yet recruiting

Competition

Competitive Landscape

116 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

3 2

Reminyl

WWim Janssens

Phase 3

1 3

Intravenous Thrombolysis

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

6 4

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 5

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 6

Aggrastat

MMedicure

Phase 3

4 7

SGLT-2 Inhibitors

Novo Nordisk

Phase 3

1 8

Proamatine

Takeda

Preclinical

2 9

Levaquin

WWim Janssens

Preclinical

3 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke4 trials

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

Withdrawn·UUniversity of Iowa·Phase 1/2·NCT04818944

Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke

Recruiting·—·Phase 3·NCT05604638·348 enrolled

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

Not yet recruiting·—·Phase 2/3·NCT06587347·302 enrolled

Show 1 more trial

Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

Unknown status·—·Phase 2/3·NCT04491695·420 enrolled

Prevention2 trials

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT03406819·1,000 enrolled

Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT03406832·1,000 enrolled

Aneurysm1 trial

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Completed·DDavid Hasan·Phase 1/2·NCT03691727·30 enrolled

Regulatory

FDA Approval Timeline[4]

May 14, 1998

AGGRASTAT

NDA NDA020912

May 17, 2002

AGGRASTAT

NDA NDA020913

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tirofiban Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tirofiban Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tirofiban Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020913). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Medicure company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedicure

Aggrastat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke4 trials

Prevention2 trials

Aneurysm1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News